[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100525537":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":25,"centralContacts":25,"locations":29,"responsibleParty":49,"collaborators":25,"id":51,"slug":25,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":25,"eligibilityCriteria":56,"healthyVolunteers":57,"sex":58,"minAge":59,"maxAge":60,"enrollmentInfo":61,"targetDuration":25,"studyType":64,"phases":65,"briefSummary":67,"conditions":68,"keywords":25,"overallStatus":32,"whyStopped":25,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"Northwestern University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Cabergoline","EXPERIMENTAL","1mg oral cabergoline administered once after patient's procedure",[13],"Drug: Cabergoline",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","1 tablet encapsulated placebo by Investigational Drug Pharmacy administered once after patient's procedure",[19],"Drug: Placebo",[21,26],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","1mg oral cabergoline given to participants once",[9],null,{"type":22,"name":15,"description":27,"armGroupLabels":28,"otherNames":25},"1 encapsulated placebo tablet given to participants after procedure",[15],[30],{"facility":31,"status":32,"city":33,"state":34,"zip":35,"country":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"Northwestern Medical Center","RECRUITING","Chicago","Illinois","60611","United States",{"type":38,"coordinates":39},"Point",[40,41],-87.65005,41.85003,{"lat":41,"lon":40},[44],{"name":45,"role":46,"phone":47,"phoneExt":25,"email":48},"Leanne McCloskey","CONTACT","312-926-8678","erin.fleurant@nm.org",{"type":50,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100525537",false,"NCT06123026","Pharmacological Inhibition of Lactation After 16 to 20 Week Abortion","Pharmacological Inhibition of Lactation After 16 to 20 Week Abortion: a Randomized Controlled Trial","Inclusion Criteria:\n\n* pregnant individuals seeking termination of pregnancy after 16w0d gestation and up to 19w6d gestation. this includes management of intrauterine demises\n* ages 18 to 50\n* con provide informed consent in English\n\nExclusion Criteria:\n\n* Age under 18 or above 50\n* gestational ages before 16 weeks 0 days or after 20 weeks 0 days\n* unable to provide written consent in English\n* hypertensive disorder\n* uncontrolled hypertension or known hypersensitivity to ergot derivatives\n* History of cardiac valvular disorders\n* history of pulmonary fibrosis\n* documented bipolar schizophrenia\n* documented allergy to medication, including lactose intolerance (placebo pill involves lactose)",true,"FEMALE","18 Years","50 Years",{"count":62,"type":63},200,"ESTIMATED","INTERVENTIONAL",[66],"PHASE4","The goal of this clinical trial is to compare breast symptoms (lactation, engorgement, etc) of individuals who undergo a procedure for second trimester of pregnancy loss between 16 weeks and 20 weeks gestational age. The participants will be randomly placed in two groups, one with a placebo tablet and one with medication called \"cabergoline\" which are taken immediately after their procedure. Researchers will compare groups to see if there are any significant differences in breast symptoms.",[69,70],"Lactation Suppressed","Second Trimester Abortion","2024-05-28",{"date":73,"type":74},"2024-05-29","ACTUAL",{"date":76,"type":74},"2023-12-18",{"date":78,"type":63},"2024-06-30",{"name":5,"class":6},1]